Yue-li Sun

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Impact of liver metastasis on the efficacy of first-line chemoimmunotherapy in extensive-stage small-cell lung cancer: a retrospective cohort study.

Impact of liver metastasis on the efficacy of first-line chemoimmunotherapy in extensive-stage small-cell lung cancer: a retrospective cohort study.

Journal: Journal of thoracic disease

Published: January 19, 2026

First case report of transformation of adenocarcinoma to adenosquamous carcinoma with giant-cell carcinoma harboring HER2 mutation after zongertinib (BI 1810631) resistance.

First case report of transformation of adenocarcinoma to adenosquamous carcinoma with giant-cell carcinoma harboring HER2 mutation after zongertinib (BI 1810631) resistance.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 22, 2025

Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).

Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).

Journal: Nature communications

Published: June 21, 2025

Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study.

Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study.

Journal: Biomarker research

Published: May 24, 2025

Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC.

Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC.

Journal: Cell reports

Published: August 21, 2023

Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial.

Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial.

Journal: EClinicalMedicine

Published: July 30, 2023

Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy.

Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy.

Journal: Molecular oncology

Published: December 14, 2022

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.

Journal: Nature medicine

Published: December 11, 2022

Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.

Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.

Journal: Clinical lung cancer

Published: June 21, 2021

A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway.

A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway.

Journal: BMC cancer

Published: June 23, 2019

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 07, 2017

Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies.

Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: July 05, 2017

Showing 1-12 of 13

Last Updated: 09/26/2026